Effect of the triazolobenzodiazepine estazolam on hepatic drug-metabolizing enzyme activity in rats.
Oral doses of the sedative/hypnotic estazolam (500 mg kg-1 day-1) to rats for 21 days caused statistically significant increases in liver weight, ascorbate excretion, cytochrome P-450 concentrations, and in aniline hydroxylase, ethylmorphine N-demethylase and glutathione S-transferase activities, as did approximately equivalent doses of flurazepam hydrochloride. Histologically, the centrilobular hepatocytes were enlarged. Some of these parameters were also increased after doses of estazolam of 100 mg kg-1 day-1, but not after 5 mg kg-1 day-1, which is about 50-fold greater than a clinical dose. Estazolam was a much less potent enzyme inducer than phenobarbitone under the conditions of these studies.
D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D004949:Estazolam / Q000494:pharmacology*; D005479:Flurazepam / Q000494:pharmacology; D008099:Liver / Q000201:enzymology*; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D009567:Nitrazepam / Q000494:pharmacology; D009929:Organ Size / Q000187:drug effects; D010088:Oxidoreductases / Q000378:metabolism*; D011506:Proteins / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains
D014151:Anti-Anxiety Agents; D011506:Proteins; D004949:Estazolam; D009567:Nitrazepam; D006899:Mixed Function Oxygenases; D010088:Oxidoreductases; D005479:Flurazepam